A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01915732
First received: April 5, 2013
Last updated: August 11, 2014
Last verified: August 2014
  Purpose

This is a multicentre, randomized, assessor-blind, comparator-controlled evaluation of the efficacy, safety, and tolerability of Duac™Once Daily Gel and clindamycin phosphate gel in the topical treatment of mild to moderate facial acne vulgaris. A total of 1020 subjects will be enrolled, 510 per study arm. The subjects will be males and females between 12 and 45 years of age, inclusive, at the time of consent, who have mild to moderate facial acne vulgaris.

Subjects will use Duac™Once Daily Gel (once daily in the evening) or clindamycin phosphate gel twice daily (once in the morning and once in the evening) for 12 weeks. The subjects will be evaluated for change in lesion counts, investigator's static global assessment (ISGA), subject's global assessment (SGA), local tolerability and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit.


Condition Intervention Phase
Acne Vulgaris
Drug: Duac™Once Daily Gel
Drug: 1% clindamycin phosphate gel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomized, Assessor-blind, Comparator-Controlled, Parallel-Group Clinical Trial to Establish the Efficacy and Safety of Duac™(1% Clindamycin as Clindamycin Phosphate and 5% Benzoyl Peroxide) Once Daily Gel Compared With Clindamycin Phosphate Gel (1% Clindamycin as Clindamycin Phosphate) Twice Daily in the Treatment of Mild to Moderate Acne Vulgaris.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Lesion count [ Time Frame: Change from baseline at week 12. ] [ Designated as safety issue: No ]
    a count of inflammatory lesions (papules, pustules, nodules, and cysts), noninflammatory lesions (open and closed comedones) and total lesions at each study visit. Lesion counts are confined to the face.

  • ISGA [ Time Frame: Change from baseline at week 12. ] [ Designated as safety issue: No ]
    investigator's stastic global assesment


Secondary Outcome Measures:
  • subjects global assesment [ Time Frame: Change from baseline at weeks 1, 2, 4, 8 and 12 ] [ Designated as safety issue: No ]
  • Quality of life assessments [ Time Frame: Change from baseline at weeks 1, 2, 4, 8 and 12 ] [ Designated as safety issue: No ]
    DQLI, dermatology quality of life index; CDQLI, children dermatology quality of life index

  • Local Tolerability Assessment by Investigators [ Time Frame: Change from baseline at weeks 1, 2, 4, 8 and 12 ] [ Designated as safety issue: Yes ]
    The efficacy assessor will assess erythema, dryness, and peeling of the face

  • Local Tolerability Assessment by Subjects [ Time Frame: Change from baseline at weeks 1, 2, 4, 8 and 12 ] [ Designated as safety issue: Yes ]
    The subject will assess burning/stinging and pruritus separately of the face

  • Lesion Counts [ Time Frame: Percent change in inflammatory and noninflammatory lesion counts from Baseline to Week 12. ] [ Designated as safety issue: No ]
    inflammatory and noninflammatory lesion counts

  • ISGA [ Time Frame: Proportion of subjects who have an ISGA score of 0 or 1 at Week 12. ] [ Designated as safety issue: No ]

Enrollment: 1018
Study Start Date: April 2013
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Duac™Once Daily Gel
Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
Drug: 1% clindamycin phosphate gel
1% clindamycin as clindamycin phosphate
Active Comparator: 1% clindamycin phosphate gel
Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
Drug: Duac™Once Daily Gel
1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide

  Eligibility

Ages Eligible for Study:   12 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects between 12 and 45 years of age, inclusive age will be calculated by date of birth, from 0 at birth.
  2. Subjects who have:

    i. A minimum of 17 but not more than 60 facial inflammatory lesions (papules plus pustules), and no more than 1 facial nodular lesion, with NO cystic lesions.

    and ii. A minimum of 20 but not more than 125 facial noninflammatory lesions (open and closed comedones).

  3. Subjects who have an ISGA score of 2 or 3 at Baseline.
  4. Subjects 18 years of age or older must provide written informed consent (according to any local or national authorization requirements). Subjects under the legal age of consent must provide assent and have written informed consent of both the subject and a parent or the legal guardian (according to any local or national authorization requirements).
  5. Subjects who are willing and able to complete the study, to understand and comply with the requirements of the study, abide by the restrictions, apply the medication as instructed, and return for the required study visits.
  6. Subjects who are in good health and free from any clinically significant disease, other than acne vulgaris, that might interfere with the study evaluations.
  7. Female subjects of childbearing potential must have a negative pregnancy test at baseline. Sexually active females of childbearing potential participating in the study must use a medically acceptable method of contraception for at least 6 consecutive months prior to start of study treatment, and must use a medically acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses. Medically acceptable contraceptive methods include the following:

    • Hormonal contraception, including oral, injectable, or implantable methods started at least 6 months prior to screening.
    • Reliable barrier methods include condoms and diaphragms. A cervical cap is also a reliable barrier method, provided that the female subject has never given birth naturally. The combined use of a condom and spermicide constitute 2 forms of acceptable nonhormonal contraception, provided that they are both used properly. The use of spermicide alone and the improper use of condoms are inferior methods of contraception. Subjects with surgical sterilization, including tubal ligation or partner's vasectomy, must use a form of nonhormonal contraception. A barrier method or sterilization plus spermatocide are acceptable.

Females who are not currently sexually active must agree to use a medically accepted method of contraception should they become sexually active while participating in the study.

Subjects who have been treated with estrogens, androgens, or anti-androgenic agents used for prevention of pregnancy (and not for control of acne) for at least 6 consecutive months prior to the first dose of investigational product may enrol as long as they do not expect to change dose, drug, or discontinue use during the study.

Exclusion Criteria:

  1. Female subjects who are pregnant, trying to become pregnant, or who are lactating.
  2. Subjects who have cystic acne lesions, acne conglobata, acne fulminans, or secondary acne (e.g. chloracne or drug-induced acne).
  3. Subjects who have any clinically relevant finding at their baseline physical examination or medical history such as severe systemic diseases or diseases of the facial skin other than acne vulgaris.
  4. Subjects who have facial hair that may prevent the accurate assessment of acne vulgaris grade or lesion count.
  5. Subjects who have a history or presence of regional enteritis or inflammatory bowel disease (e.g. ulcerative colitis, pseudomembranous colitis, chronic diarrhoea, or a history of antibiotic-associated colitis, bloody diarrhoea) or similar symptoms.
  6. Subjects who have used a prohibited medication, or undergone a prohibited procedure or treatment within the required washout period.
  7. Subjects who have a known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, or excipients of the investigational product.
  8. Subjects who are employees of a clinical research organization involved in the study, Stiefel, or GSK or who are an immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of an employee, the investigator, or his/her study staff.
  9. Subjects who have a member of the same household in this study at the same time.
  10. Subjects who have used traditional remedies known to affect acne vulgaris within the last 4 weeks.
  11. Subjects who have had any major illness within 30 days before study enrolment.
  12. Subjects who have any other condition that in the judgement of the investigator would put the subject at unacceptable risk for participation in the study.
  13. Subjects who have participated in any clinical trials or taken any investigate drugs within 4 weeks before study enrolment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01915732

Locations
China, Guangdong
GSK Investigational Site
Guangzhou, Guangdong, China, 510080
GSK Investigational Site
Guangzhou, Guangdong, China, 510120
GSK Investigational Site
Guangzhou, Guangdong, China, 510010
China, Hebei
GSK Investigational Site
Wuhan, Hebei, China, 430071
China, Hunan
GSK Investigational Site
Changsha, Hunan, China, 410013
GSK Investigational Site
Changsha, Hunan, China, 410011
China, Jiangsu
GSK Investigational Site
Nanjing, Jiangsu, China, 210029
GSK Investigational Site
Nanjing, Jiangsu, China, 210042
China, Jilin
GSK Investigational Site
Changchun, Jilin, China, 130041
China, Shandong
GSK Investigational Site
Jinan, Shandong, China, 250022
China, Shanxi
GSK Investigational Site
Xian, Shanxi, China, 710032
China, Zhejiang
GSK Investigational Site
Hangzhou, Zhejiang, China, 310009
GSK Investigational Site
Hangzhou, Zhejiang, China, 310003
China
GSK Investigational Site
Beijing, China, 100020
GSK Investigational Site
Beijing, China, 100730
GSK Investigational Site
Beijing, China, 100034
GSK Investigational Site
Beijing, China, 100036
GSK Investigational Site
Chongqing, China, 400038
GSK Investigational Site
Shanghai, China, 200032
GSK Investigational Site
Shanghai, China, 200040
GSK Investigational Site
Shanghai, China, 200092
GSK Investigational Site
Shanghai, China, 200433
GSK Investigational Site
Shanghai, China, 200025
GSK Investigational Site
Wuhan, China, 430022
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01915732     History of Changes
Other Study ID Numbers: 114543
Study First Received: April 5, 2013
Last Updated: August 11, 2014
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Facial Dermatoses
Sebaceous Gland Diseases
Benzoyl Peroxide
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 14, 2014